Loading...
Docoh

Athira Pharma (ATHA)

News

From Benzinga Pro
Athira Pharma Q1 EPS $(0.56) Down From $(0.25) YoY
12 May 22
Earnings, News
Athira Pharma (NASDAQ:ATHA) reported quarterly losses of $(0.56) per share. This is a 124 percent decrease over losses of $(0.25) per share from the same period last year.
Benzinga's Top Ratings Upgrades, Downgrades For May 10, 2022
10 May 22
Upgrades, Downgrades, Initiation, Intraday Update, Analyst Ratings
Upgrades
BTIG Initiates Coverage On Athira Pharma with Buy Rating, Announces Price Target of $33
10 May 22
News, Price Target, Initiation, Analyst Ratings
BTIG analyst Thomas Shrader initiates coverage on Athira Pharma (NASDAQ:ATHA) with a Buy rating and announces Price Target of $33.
Athira Pharma Extends Ongoing Open Label Extension Study For LIFT-AD And ACT-AD Clinical Trials Of Fosgonimeton For Mild To Moderate Alzheimer's Disease
9 May 22
Biotech, News, FDA, General
Athira Pharma, Inc. (NASDAQ:ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that it is extending
Ric Kayne Issues Letter To Athira Shareholders Highlighting Why Immediate Board Change Is Required
27 Apr 22
News
Details Numerous Recent Missteps by Current Athira Board That Have Led to Significant Destruction of Shareholder Value and Outlines the Urgent Need for Change Releases Video at www.SaveAthira.com Highlighting
Benzinga's Top Ratings Upgrades, Downgrades For April 21, 2022
21 Apr 22
Upgrades, Downgrades, Initiation, Intraday Update, Analyst Ratings
Berenberg Initiates Coverage On Athira Pharma with Buy Rating, Announces Price Target of $33
21 Apr 22
News, Price Target, Initiation, Analyst Ratings
Berenberg analyst Esther Hong initiates coverage on Athira Pharma (NASDAQ:ATHA) with a Buy rating and announces Price Target of $33.
Athira Files Definitive Proxy Statement And Mails Letter To Shareholders
5 Apr 22
News
Athira Files Definitive Proxy Statement and Mails Letter to Shareholders Urges shareholders to vote "FOR" Athira's highly qualified, independent director nominees – Joseph Edelman, John M. Fluke, Jr.
Athira Pharma Doses First Subject In Phase 1 Clinical Trial Of HGF/MET Positive Modulator, ATH-1020, An Orally Available Small Molecule For Neuropsychiatric Conditions
4 Apr 22
Biotech, News, FDA, General
Athira Pharma, Inc. (NASDAQ:ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that the first subject
The Daily Biotech Pulse: MEI Pharma Wilts On Adverse Regulatory Development, Decision Day For Zogenix, AN2 Therapeutics IPO
25 Mar 22
Biotech, Earnings, News, Penny Stocks, Small Cap, FDA, General
Here's a roundup of top developments in the biotech space over the last 24 hours.
The Daily Biotech Pulse: Novartis Prostate Cancer Drug Lands FDA Approval, Ligand Announces SPAC Deal To Spin Off Antibody Business, Lilly's Lung Cancer Therapy Hit With CRL
24 Mar 22
Biotech, News, Penny Stocks, Offerings, Small Cap, FDA, General
Here's a roundup of top developments in the biotech space over the last 24 hours:
Earnings Scheduled For March 24, 2022
24 Mar 22
Earnings, News, Pre-Market Outlook, Markets
Companies Reporting Before The Bell • iHuman (NYSE:IH) is likely to report earnings for its fourth quarter.
Earnings Preview: Athira Pharma
23 Mar 22
Earnings
Athira Pharma (NASDAQ:ATHA) is set to give its latest quarterly earnings report on Thursday, 2022-03-24. Here's what investors need to know before the announcement. Analysts estimate that Athira Pharma will report an earnings per share (EPS) of $-0.54.
The Week Ahead In Biotech (March 20-26): Focus On Zogenix FDA Decision, Dermatology Conference Presentations & Earnings
20 Mar 22
Biotech, News, Penny Stocks, Small Cap, FDA, Top Stories, General
Biotech stocks rebounded along with the broader market in the week ending March 18, as risk appetite returned. Multiple conference presentations, clinical readouts and earnings news dictated sentiment during the week.

Press releases

From Benzinga Pro
ATHIRA PHARMA INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Athira Pharma, Inc. - ATHA
27 May 22
Press Releases
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that KSF continues its investigation into Athira Pharma, Inc.
ATHIRA ALERT: Bragar Eagel & Squire, P.C. Is Investigating Athira Pharma, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
20 May 22
Press Releases
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Athira Pharma, Inc. (NASDAQ:ATHA) on behalf of long-term stockholders following a class
Shareholders Approve the Election of All Three Athira Director Nominees at 2022 Annual Meeting
19 May 22
News, Management, Press Releases
BOTHELL, Wash., May 19, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ:ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow
Athira Issues Statement in Response to Richard A. Kayne's Suspension of His Proxy Contest
16 May 22
Press Releases
Athira Board Unanimously Recommends Shareholders Vote "FOR" its Highly Qualified Nominees – Joseph Edelman, John M. Fluke, Jr. and Grant Pickering – on the WHITE proxy card BOTHELL, Wash., May 16, 2022 (GLOBE
ATHIRA PHARMA INVESTIGATION CONTINUED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Athira Pharma, Inc. - ATHA
13 May 22
Press Releases
NEW ORLEANS, May 13, 2022 /PRNewswire/ -- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that KSF continues its
Athira Pharma Reports First Quarter 2022 Financial Results and Provides Pipeline and Business Updates
12 May 22
Biotech, Earnings, Press Releases, General
BOTHELL, Wash., May 12, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ:ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow
Ric Kayne Issues Letter to Athira Shareholders Highlighting Need for Immediate Change to Athira Board
12 May 22
Press Releases
Details Poor Decision-Making by Current Athira Board Leading to Destruction of Shareholder Value and Outlines the Urgent Need for Change Urges Athira Shareholders to VOTE their BLUE Proxy Card TODAY Richard A. (Ric)
Athira Urges Shareholders to Support its Director Nominees at May 19 Annual Meeting
11 May 22
Press Releases
Urges Shareholders to Vote TODAY "FOR" Athira's Highly Qualified, Independent Director Nominees – Joseph Edelman, John M. Fluke, Jr. and Grant Pickering – on the WHITE Proxy Card BOTHELL, Wash., May 11, 2022 (GLOBE
ATHIRA PHARMA INVESTIGATION CONTINUED By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Athira Pharma, Inc. - ATHA
5 May 22
Press Releases
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that KSF continues its investigation into Athira Pharma, Inc.
Leading Independent Proxy Advisory Firm Glass Lewis Recommends that Athira Shareholders Vote "FOR" All of Athira's Highly Qualified Director Nominees
5 May 22
Health Care, Press Releases, General
Joins Institutional Shareholder Services in Recommending a Vote on Athira's WHITE Proxy Card Athira Urges Shareholders to Vote "FOR" Athira's Highly Qualified, Independent Director Nominees – Joseph Edelman, John M.
Athira Mails Letter to Shareholders Emphasizing the Company's Strong Position and Qualified Board as it Enters Pivotal Chapter
5 May 22
Press Releases
Urges Shareholders to Vote "FOR" Athira's Highly Qualified, Independent Director Nominees – Joseph Edelman, John M. Fluke, Jr. and Grant Pickering – on the WHITE Proxy Card BOTHELL, Wash., May 05, 2022 (GLOBE
Leading Proxy Advisory Firm ISS Recommends Athira Shareholders "Withhold" Support From Incumbent Directors Joseph Edelman and John Fluke
5 May 22
Press Releases
ISS Would Have Recommended Shareholders "WITHHOLD" For Full Board Due to Classified Board Structure, Calls Board's Mechanisms for Management Oversight to be "Lacking", and Highlights Numerous Other Corporate Governance
Leading Independent Proxy Advisory Firm ISS Recommends that Athira Shareholders Vote on Athira's WHITE Proxy Card
4 May 22
Press Releases
Athira Urges Shareholders to Vote "FOR" Athira's Highly Qualified, Independent Director Nominees – Joseph Edelman, John M. Fluke, Jr. and Grant Pickering – on the WHITE Proxy Card Today BOTHELL, Wash., May 04, 2022
Ric Kayne Identifies Highly Qualified CEO Candidate for Athira
4 May 22
Press Releases
Dr. Ronald Krall, Former Chief Medical Officer of GlaxoSmithKline, Willing to Become Athira's CEO To Maximize Chance of Successful Clinical Trials and Join Board Urges Board to Immediately Interview Dr. Krall Richard
ATHIRA PHARMA INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Athira Pharma, Inc. - ATHA
29 Apr 22
Press Releases
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that KSF has commenced an investigation into Athira Pharma, Inc.
Ric Kayne Issues Letter to Athira Shareholders Highlighting Why Immediate Board Change Is Required
27 Apr 22
Press Releases
Details Numerous Recent Missteps by Current Athira Board That Have Led to Significant Destruction of Shareholder Value and Outlines the Urgent Need for Change Releases Video at www.SaveAthira.com Highlighting Why Ric
Athira Files Investor Presentation Highlighting Successful Execution of its Strategy and Highly Qualified Board and Leadership
26 Apr 22
Press Releases
Urges shareholders to vote "FOR" Athira's highly qualified, independent director nominees – Joseph Edelman, John M. Fluke, Jr. and Grant Pickering – on the WHITE proxy card BOTHELL, Wash., April 26, 2022 (GLOBE
Athira Mails Letter to Shareholders Highlighting the Strength of its Board and Record of Deliberate Board Refreshment
20 Apr 22
News, Health Care, Management, Press Releases
Urges shareholders to vote "FOR" Athira's highly qualified, independent director nominees – Joseph Edelman, John M. Fluke, Jr. and Grant Pickering – on the WHITE proxy card BOTHELL, Wash., April 20, 2022 (GLOBE
ATHIRA ALERT: Bragar Eagel & Squire, P.C. is Investigating Athira Pharma, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
15 Apr 22
Press Releases
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Athira Pharma, Inc. (NASDAQ:ATHA) on behalf of long-term stockholders following a class
Ric Kayne Files Definitive Proxy Materials for Athira's 2022 Annual Meeting
11 Apr 22
Press Releases
Sends Letter to Athira's Shareholders Seeking Replacement of CEO Dr. Mark Litton Highlights New Management and Shareholder Centric Directors Are Required to Provide Proper Oversight of ATH-1017 Clinical Trials to